NEXTURNBIOSCIENCE Co., Ltd. (KOSDAQ:089140)
South Korea
· Delayed Price · Currency is KRW 2,770.00
+65.00 (2.40%)
Last updated: May 12, 2025
NEXTURNBIOSCIENCE Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -13,005 | 9,681 | -4,688 | -4,433 | -2,436 | Upgrade
|
| Depreciation & Amortization | 2,013 | 2,002 | 1,808 | 1,051 | 514.56 | Upgrade
|
| Loss (Gain) From Sale of Assets | -50.88 | -57.76 | -2,351 | -23.71 | -0.95 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 645 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 1,710 | -24,816 | -1,057 | -2,160 | -343.42 | Upgrade
|
| Loss (Gain) on Equity Investments | 13,710 | 3,524 | 4,873 | 5,227 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 362.24 | 77.26 | -92.67 | -114.86 | 1,458 | Upgrade
|
| Other Operating Activities | -4,842 | 10,859 | -75.23 | 2,542 | -936.99 | Upgrade
|
| Change in Accounts Receivable | 3,247 | -824.43 | -629.51 | 506.9 | 2,562 | Upgrade
|
| Change in Inventory | -2,242 | 1,130 | 1,200 | 1,630 | 1,188 | Upgrade
|
| Change in Accounts Payable | -823.14 | -1,254 | -679.12 | 229.68 | -2,191 | Upgrade
|
| Change in Unearned Revenue | -35.58 | 0.26 | 7.09 | -40.02 | 40.02 | Upgrade
|
| Change in Other Net Operating Assets | -1,187 | -2,937 | 494.64 | -750.74 | 381.65 | Upgrade
|
| Operating Cash Flow | -1,143 | -1,971 | -1,191 | 3,664 | 235.94 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | 1453.13% | - | Upgrade
|
| Capital Expenditures | -644.62 | -1,077 | -216.35 | -467.6 | -1,215 | Upgrade
|
| Sale of Property, Plant & Equipment | 53.5 | 307.67 | 21,014 | 25.36 | 10.02 | Upgrade
|
| Cash Acquisitions | - | - | -12,633 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -85.83 | 99.16 | -66.02 | -19.7 | -1.06 | Upgrade
|
| Investment in Securities | -8,951 | -21,685 | 12,753 | -72,697 | 1,223 | Upgrade
|
| Other Investing Activities | 6.91 | 39.9 | -392.46 | -92.19 | 0 | Upgrade
|
| Investing Cash Flow | -9,621 | -17,417 | -56,511 | -73,251 | 16.63 | Upgrade
|
| Short-Term Debt Issued | 8,151 | 1,070 | - | - | - | Upgrade
|
| Long-Term Debt Issued | 73,669 | 19,976 | 66,510 | 40,857 | - | Upgrade
|
| Total Debt Issued | 81,820 | 21,046 | 66,510 | 40,857 | - | Upgrade
|
| Short-Term Debt Repaid | -221.1 | -3,235 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -74,024 | -1,525 | -22,467 | -3,389 | -25.84 | Upgrade
|
| Total Debt Repaid | -74,245 | -4,760 | -22,467 | -3,389 | -25.84 | Upgrade
|
| Net Debt Issued (Repaid) | 7,575 | 16,286 | 44,043 | 37,467 | -25.84 | Upgrade
|
| Issuance of Common Stock | - | 999.99 | 4,206 | - | - | Upgrade
|
| Repurchase of Common Stock | - | -81.24 | - | - | - | Upgrade
|
| Dividends Paid | - | - | - | - | -1,069 | Upgrade
|
| Other Financing Activities | -46.33 | 5,287 | -311.39 | -10.1 | - | Upgrade
|
| Financing Cash Flow | 7,528 | 22,492 | 47,937 | 37,457 | -1,095 | Upgrade
|
| Foreign Exchange Rate Adjustments | 101.14 | -11.15 | -223.57 | 61.85 | -691.53 | Upgrade
|
| Net Cash Flow | -3,134 | 3,093 | -9,989 | -32,068 | -1,534 | Upgrade
|
| Free Cash Flow | -1,788 | -3,047 | -1,407 | 3,197 | -979.05 | Upgrade
|
| Free Cash Flow Margin | -5.65% | -7.39% | -6.00% | 18.84% | -10.11% | Upgrade
|
| Free Cash Flow Per Share | -163.53 | -302.11 | -207.29 | 498.56 | -152.68 | Upgrade
|
| Cash Interest Paid | 4,195 | 3,333 | 2,232 | 205.83 | - | Upgrade
|
| Cash Income Tax Paid | 3,615 | -25.64 | 405.86 | -845.73 | 1,216 | Upgrade
|
| Levered Free Cash Flow | -16,434 | 5,481 | -17,895 | 15,606 | - | Upgrade
|
| Unlevered Free Cash Flow | -13,018 | 8,029 | -14,353 | 17,116 | - | Upgrade
|
| Change in Net Working Capital | 13,397 | -7,798 | 13,048 | -18,046 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.